Interleukin-7: Fuel for the autoimmune attack

Journal of Autoimmunity

Volumn 45, Issue , 2013, Pages 40-48

  Dooms, Hans ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoreactive T cells; Interleukin 7

Indexed keywords

INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CYTOKINE PRODUCTION; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

AUTOREACTIVE T-CELLS; INTERLEUKIN-7;

ANIMALS; ANTIBODIES, BLOCKING; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CELL SURVIVAL; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HOMEOSTASIS; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-7; MICE; POLYMORPHISM, GENETIC; RECEPTORS, INTERLEUKIN-7; T-LYMPHOCYTES;

EID: 84884280668     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.06.007     Document Type: Review

References (130)

1. Bluestone J.A., Bour-Jordan H. Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harbor Perspectives in Biology 2012, 4.
2. Croft M., Benedict C.A., Ware C.F. Clinical targeting of the TNF and TNFR superfamilies. Nature Reviews Drug Discovery 2013, 12:147-168.
3. Ariza M.E., Williams M.V., Wong H.K. Targeting IL-17 in psoriasis: from cutaneous immunobiology to clinical application. Clinical Immunology 2013, 146:131-139.
4. Long S.A., Buckner J.H., Greenbaum C.J. IL-2 therapy in type 1 diabetes: "Trials" and tribulations. Clinical Immunology 2013, 10.1016/j.clim.2013.02.005.
5. Morris G.P., Allen P.M. How the TCR balances sensitivity and specificity for the recognition of self and pathogens. Nature Immunology 2012, 13:121-128.
6. Sprent J., Surh C.D. Normal T cell homeostasis: the conversion of naive cells into memory-phenotype cells. Nature Immunology 2011, 12:478-484.
7. Barron L., Dooms H., Hoyer K.K., Kuswanto W., Hofmann J., O'Gorman W.E., et al. Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells. Journal of Immunology 2010, 185:6426-6430.
8. Dooms H., Kahn E., Knoechel B., Abbas A.K. IL-2 induces a competitive survival advantage in T lymphocytes. Journal of Immunology 2004, 172:5973-5979.
9. Fontenot J.D., Rasmussen J.P., Gavin M.A., Rudensky A.Y. Afunction for interleukin 2 in Foxp3-expressing regulatory T cells. Nature Immunology 2005, 6:1142-1151.
10. Smith K.A. Interleukin-2: inception, impact, and implications. Science 1988, 240:1169-1176.
11. Kurt-Jones E.A., Hamberg S., Ohara J., Paul W.E., Abbas A.K. Heterogeneity of helper/inducer T lymphocytes. I. Lymphokine production and lymphokine responsiveness. The Journal of Experimental Medicine 1987, 166:1774-1787.
12. Lichtman A.H., Kurt-Jones E.A., Abbas A.K. B-cell stimulatory factor 1 and not interleukin 2 is the autocrine growth factor for some helper T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 1987, 84:824-827.
13. Swain S.L., Weinberg A.D., English M., Huston G. IL-4 directs the development of Th2-like helper effectors. Journal of Immunology 1990, 145:3796-3806.
14. Le Gros G., Ben-Sasson S.Z., Seder R., Finkelman F.D., Paul W.E. Generation of interleukin 4 (IL-4)-producing cells invivo and invitro: IL-2 and IL-4 are required for invitro generation of IL-4-producing cells. The Journal of Experimental Medicine 1990, 172:921-929.
15. Noelle R.J., Nowak E.C. Cellular sources and immune functions of interleukin-9. Nature Reviews Immunology 2010, 10:683-687.
16. Lodolce J.P., Boone D.L., Chai S., Swain R.E., Dassopoulos T., Trettin S., et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998, 9:669-676.
17. Dooms H., Desmedt M., Vancaeneghem S., Rottiers P., Goossens V., Fiers W., et al. Quiescence-inducing and antiapoptotic activities of IL-15 enhance secondary CD4+ T cell responsiveness to antigen. Journal of Immunology 1998, 161:2141-2150.
18. Nurieva R., Yang X.O., Martinez G., Zhang Y., Panopoulos A.D., Ma L., et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007, 448:480-483.
19. Yi J.S., Du M., Zajac A.J. Avital role for interleukin-21 in the control of a chronic viral infection. Science 2009, 324:1572-1576.
20. Jiang Q., Li W.Q., Aiello F.B., Mazzucchelli R., Asefa B., Khaled A.R., et al. Cell biology of IL-7, a key lymphotrophin. Cytokine & Growth Factor Reviews 2005, 16:513-533.
21. Park L.S., Martin U., Garka K., Gliniak B., Di Santo J.P., Muller W., et al. Cloning of the murine thymic stromal lymphopoietin (TSLP) receptor: formation of a functional heteromeric complex requires interleukin 7 receptor. The Journal of Experimental Medicine 2000, 192:659-670.
22. Hara T., Shitara S., Imai K., Miyachi H., Kitano S., Yao H., et al. Identification of IL-7-producing cells in primary and secondary lymphoid organs using IL-7-GFP knock-in mice. Journal of Immunology 2012, 189:1577-1584.
23. Link A., Vogt T.K., Favre S., Britschgi M.R., Acha-Orbea H., Hinz B., et al. Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. Nature Immunology 2007, 8:1255-1265.
24. Porter B.O., Malek T.R. Thymic and intestinal intraepithelial T lymphocyte development are each regulated by the gammac-dependent cytokines IL-2, IL-7, and IL-15. Seminars in Immunology 2000, 12:465-474.
25. Van De Wiele C.J., Marino J.H., Murray B.W., Vo S.S., Whetsell M.E., Teague T.K. Thymocytes between the beta-selection and positive selection checkpoints are nonresponsive to IL-7 as assessed by STAT-5 phosphorylation. Journal of Immunology 2004, 172:4235-4244.
26. Yu Q., Park J.H., Doan L.L., Erman B., Feigenbaum L., Singer A. Cytokine signal transduction is suppressed in preselection double-positive thymocytes and restored by positive selection. The Journal of Experimental Medicine 2006, 203:165-175.
27. Park J.H., Adoro S., Guinter T., Erman B., Alag A.S., Catalfamo M., et al. Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells. Nature Immunology 2010, 11:257-264.
28. Samaridis J., Casorati G., Traunecker A., Iglesias A., Gutierrez J.C., Muller U., et al. Development of lymphocytes in interleukin 7-transgenic mice. European Journal of Immunology 1991, 21:453-460.
29. Rich B.E., Campos-Torres J., Tepper R.I., Moreadith R.W., Leder P. Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. The Journal of Experimental Medicine 1993, 177:305-316.
30. Uehira M., Matsuda H., Hikita I., Sakata T., Fujiwara H., Nishimoto H. The development of dermatitis infiltrated by gamma delta T cells in IL-7 transgenic mice. International Immunology 1993, 5:1619-1627.
31. Munitic I., Williams J.A., Yang Y., Dong B., Lucas P.J., El Kassar N., et al. Dynamic regulation of IL-7 receptor expression is required for normal thymopoiesis. Blood 2004, 104:4165-4172.
32. Namen A.E., Lupton S., Hjerrild K., Wignall J., Mochizuki D.Y., Schmierer A., et al. Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature 1988, 333:571-573.
33. Grabstein K.H., Waldschmidt T.J., Finkelman F.D., Hess B.W., Alpert A.R., Boiani N.E., et al. Inhibition of murine B and T lymphopoiesis invivo by an anti-interleukin 7 monoclonal antibody. The Journal of Experimental Medicine 1993, 178:257-264.
34. Peschon J.J., Morrissey P.J., Grabstein K.H., Ramsdell F.J., Maraskovsky E., Gliniak B.C., et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. The Journal of Experimental Medicine 1994, 180:1955-1960.
35. von Freeden-Jeffry U., Vieira P., Lucian L.A., McNeil T., Burdach S.E., Murray R. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. The Journal of Experimental Medicine 1995, 181:1519-1526.
36. Carvalho T.L., Mota-Santos T., Cumano A., Demengeot J., Vieira P. Arrested B lymphopoiesis and persistence of activated B cells in adult interleukin 7(-/)- mice. The Journal of Experimental Medicine 2001, 194:1141-1150.
37. Polic B., Kunkel D., Scheffold A., Rajewsky K. How alpha beta T cells deal with induced TCR alpha ablation. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:8744-8749.
38. Viret C., Wong F.S., Janeway C.A. Designing and maintaining the mature TCR repertoire: the continuum of self-peptide:self-MHC complex recognition. Immunity 1999, 10:559-568.
39. Tan J.T., Dudl E., LeRoy E., Murray R., Sprent J., Weinberg K.I., et al. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:8732-8737.
40. Rathmell J.C., Farkash E.A., Gao W., Thompson C.B. IL-7 enhances the survival and maintains the size of naive T cells. Journal of Immunology 2001, 167:6869-6876.
41. Dooms H., Abbas A.K. Control of CD4+ T-cell memory by cytokines and costimulators. Immunological Reviews 2006, 211:23-38.
42. Opferman J.T., Letai A., Beard C., Sorcinelli M.D., Ong C.C., Korsmeyer S.J. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003, 426:671-676.
43. Schluns K.S., Kieper W.C., Jameson S.C., Lefrancois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells invivo. Nature Immunology 2000, 1:426-432.
44. Kaech S.M., Tan J.T., Wherry E.J., Konieczny B.T., Surh C.D., Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nature Immunology 2003, 4:1191-1198.
45. Dooms H., Wolslegel K., Lin P., Abbas A.K. Interleukin-2 enhances CD4+ T cell memory by promoting the generation of IL-7R alpha-expressing cells. The Journal of Experimental Medicine 2007, 204:547-557.
46. Seddon B., Tomlinson P., Zamoyska R. Interleukin 7 and T cell receptor signals regulate homeostasis of CD4 memory cells. Nature Immunology 2003, 4:680-686.
47. Kondrack R.M., Harbertson J., Tan J.T., McBreen M.E., Surh C.D., Bradley L.M. Interleukin 7 regulates the survival and generation of memory CD4 cells. The Journal of Experimental Medicine 2003, 198:1797-1806.
48. Li J., Huston G., Swain S.L. IL-7 promotes the transition of CD4 effectors to persistent memory cells. The Journal of Experimental Medicine 2003, 198:1807-1815.
49. Buentke E., Mathiot A., Tolaini M., Di Santo J., Zamoyska R., Seddon B. Do CD8 effector cells need IL-7R expression to become resting memory cells?. Blood 2006, 108:1949-1956.
50. Swain S.L., Hu H., Huston G. Class II-independent generation of CD4 memory T cells from effectors. Science 1999, 286:1381-1383.
51. Murali-Krishna K., Lau L.L., Sambhara S., Lemonnier F., Altman J., Ahmed R. Persistence of memory CD8 T cells in MHC class I-deficient mice. Science 1999, 286:1377-1381.
52. Penaranda C., Kuswanto W., Hofmann J., Kenefeck R., Narendran P., Walker L.S., et al. IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:12668-12673.
53. Kimura M.Y., Pobezinsky L.A., Guinter T.I., Thomas J., Adams A., Park J.H., et al. IL-7 signaling must be intermittent, not continuous, during CD8(+) T cell homeostasis to promote cell survival instead of cell death. Nature Immunology 2013, 14:143-151.
54. Wang R., Green D.R. Metabolic checkpoints in activated T cells. Nature Immunology 2012, 13:907-915.
55. Frauwirth K.A., Riley J.L., Harris M.H., Parry R.V., Rathmell J.C., Plas D.R., et al. The CD28 signaling pathway regulates glucose metabolism. Immunity 2002, 16:769-777.
56. Wofford J.A., Wieman H.L., Jacobs S.R., Zhao Y., Rathmell J.C. IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival. Blood 2008, 111:2101-2111.
57. Akashi K., Kondo M., von Freeden-Jeffry U., Murray R., Weissman I.L. Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice. Cell 1997, 89:1033-1041.
58. Khaled A.R., Li W.Q., Huang J., Fry T.J., Khaled A.S., Mackall C.L., et al. Bax deficiency partially corrects interleukin-7 receptor alpha deficiency. Immunity 2002, 17:561-573.
59. Pellegrini M., Bouillet P., Robati M., Belz G.T., Davey G.M., Strasser A. Loss of Bim increases T cell production and function in interleukin 7 receptor-deficient mice. The Journal of Experimental Medicine 2004, 200:1189-1195.
60. Delgoffe G.M., Kole T.P., Zheng Y., Zarek P.E., Matthews K.L., Xiao B., et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009, 30:832-844.
61. Michalek R.D., Gerriets V.A., Jacobs S.R., Macintyre A.N., MacIver N.J., Mason E.F., et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. Journal of Immunology 2011, 186:3299-3303.
62. Monti P., Brigatti C., Krasmann M., Ziegler A.G., Bonifacio E. Concentration and activity of the soluble form of the interleukin-7 receptor alpha in type I diabetes identifies an interplay between hyperglycemia and immune function. Diabetes 2013, 62:2500-2508.
63. Crawley A.M., Faucher S., Angel J.B. Soluble IL-7R alpha (sCD127) inhibits IL-7 activity and is increased in HIV infection. Journal of Immunology 2010, 184:4679-4687.
64. Lundstrom W., Highfill S., Walsh S.T., Beq S., Morse E., Kockum I., et al. Soluble IL7Ralpha potentiates IL-7 bioactivity and promotes autoimmunity. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:E1761-E1770.
65. Capitini C.M., Chisti A.A., Mackall C.L. Modulating T-cell homeostasis with IL-7: preclinical and clinical studies. Journal of Internal Medicine 2009, 266:141-153.
66. Melchionda F., Fry T.J., Milliron M.J., McKirdy M.A., Tagaya Y., Mackall C.L. Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. The Journal of Clinical Investigation 2005, 115:1177-1187.
67. Pellegrini M., Calzascia T., Toe J.G., Preston S.P., Lin A.E., Elford A.R., et al. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell 2011, 144:601-613.
68. Pellegrini M., Calzascia T., Elford A.R., Shahinian A., Lin A.E., Dissanayake D., et al. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nature Medicine 2009, 15:528-536.
69. Luther S.A., Ansel K.M., Cyster J.G. Overlapping roles of CXCL13, interleukin 7 receptor alpha, and CCR7 ligands in lymph node development. The Journal of Experimental Medicine 2003, 197:1191-1198.
70. Meier D., Bornmann C., Chappaz S., Schmutz S., Otten L.A., Ceredig R., et al. Ectopic lymphoid-organ development occurs through interleukin 7-mediated enhanced survival of lymphoid-tissue-inducer cells. Immunity 2007, 26:643-654.
71. Penaranda C., Tang Q., Ruddle N.H., Bluestone J.A. Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs. Diabetes 2010, 59:1461-1468.
72. Huang H.Y., Luther S.A. Expression and function of interleukin-7 in secondary and tertiary lymphoid organs. Seminars in Immunology 2012, 24:175-189.
73. Guimond M., Veenstra R.G., Grindler D.J., Zhang H., Cui Y., Murphy R.D., et al. Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. Nature Immunology 2009, 10:149-157.
74. Alderson M.R., Tough T.W., Ziegler S.F., Grabstein K.H. Interleukin 7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes. The Journal of Experimental Medicine 1991, 173:923-930.
75. Standiford T.J., Strieter R.M., Allen R.M., Burdick M.D., Kunkel S.L. IL-7 up-regulates the expression of IL-8 from resting and stimulated human blood monocytes. Journal of Immunology 1992, 149:2035-2039.
76. Vonarbourg C., Mortha A., Bui V.L., Hernandez P.P., Kiss E.A., Hoyler T., et al. Regulated expression of nuclear receptor RORgammat confers distinct functional fates to NK cell receptor-expressing RORgammat(+) innate lymphocytes. Immunity 2010, 33:736-751.
77. Cella M., Otero K., Colonna M. Expansion of human NK-22 cells with IL-7, IL-2, and IL-1beta reveals intrinsic functional plasticity. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:10961-10966.
78. He Y.W., Malek T.R. Interleukin-7 receptor alpha is essential for the development of gamma delta+T cells, but not natural killer cells. The Journal of Experimental Medicine 1996, 184:289-293.
79. Gregory S.G., Schmidt S., Seth P., Oksenberg J.R., Hart J., Prokop A., et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nature Genetics 2007, 39:1083-1091.
80. Lundmark F., Duvefelt K., Iacobaeus E., Kockum I., Wallstrom E., Khademi M., et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nature Genetics 2007, 39:1108-1113.
81. International Multiple Sclerosis Genetics Consortium, Hafler D.A., Compston A., Sawcer S., Lander E.S., Daly M.J., et al. Risk alleles for multiple sclerosis identified by a genomewide study. The New England Journal of Medicine 2007, 357:851-862.
82. Todd J.A., Walker N.M., Cooper J.D., Smyth D.J., Downes K., Plagnol V., et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nature Genetics 2007, 39:857-864.
83. Mells G.F., Floyd J.A., Morley K.I., Cordell H.J., Franklin C.S., Shin S.Y., et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nature Genetics 2011, 43:329-332.
84. Liu X., Leung S., Wang C., Tan Z., Wang J., Guo T.B., et al. Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. Nature Medicine 2010, 16:191-197.
85. Lee L.F., Axtell R., Tu G.H., Logronio K., Dilley J., Yu J., et al. IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-beta in multiple sclerosis. Science Translational Medicine 2011, 3:93ra68.
86. Lee L.F., Logronio K., Tu G.H., Zhai W., Ni I., Mei L., et al. Anti-IL-7 receptor-alpha reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:12674-12679.
87. Hartgring S.A., Willis C.R., Alcorn D., Nelson L.J., Bijlsma J.W., Lafeber F.P., et al. Blockade of the interleukin-7 receptor inhibits collagen-induced arthritis and is associated with reduction of T cell activity and proinflammatory mediators. Arthritis and Rheumatism 2010, 62:2716-2725.
88. Kreft K.L., Verbraak E., Wierenga-Wolf A.F., van Meurs M., Oostra B.A., Laman J.D., et al. The IL-7Ralpha pathway is quantitatively and functionally altered in CD8 T cells in multiple sclerosis. Journal of Immunology 2012, 188:1874-1883.
89. Wucherpfennig K.W., Newcombe J., Li H., Keddy C., Cuzner M.L., Hafler D.A. Gamma delta T-cell receptor repertoire in acute multiple sclerosis lesions. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:4588-4592.
90. Shoda L.K., Young D.L., Ramanujan S., Whiting C.C., Atkinson M.A., Bluestone J.A., et al. Acomprehensive review of interventions in the NOD mouse and implications for translation. Immunity 2005, 23:115-126.
91. Yamanouchi J., Rainbow D., Serra P., Howlett S., Hunter K., Garner V.E., et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nature Genetics 2007, 39:329-337.
92. Ansari M.J., Salama A.D., Chitnis T., Smith R.N., Yagita H., Akiba H., et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. The Journal of Experimental Medicine 2003, 198:63-69.
93. Wang J., Yoshida T., Nakaki F., Hiai H., Okazaki T., Honjo T. Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:11823-11828.
94. Heninger A.K., Theil A., Wilhelm C., Petzold C., Huebel N., Kretschmer K., et al. IL-7 abrogates suppressive activity of human CD4+CD25+FOXP3+ regulatory T cells and allows expansion of alloreactive and autoreactive T cells. Journal of Immunology 2012, 189:5649-5658.
95. van Roon J.A., Glaudemans K.A., Bijlsma J.W., Lafeber F.P. Interleukin 7 stimulates tumour necrosis factor alpha and Th1 cytokine production in joints of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2003, 62:113-119.
96. De Benedetti F., Massa M., Pignatti P., Kelley M., Faltynek C.R., Martini A. Elevated circulating interleukin-7 levels in patients with systemic juvenile rheumatoid arthritis. The Journal of Rheumatology 1995, 22:1581-1585.
97. van Roon J.A., Verweij M.C., Wijk M.W., Jacobs K.M., Bijlsma J.W., Lafeber F.P. Increased intraarticular interleukin-7 in rheumatoid arthritis patients stimulates cell contact-dependent activation of CD4(+) T cells and macrophages. Arthritis and Rheumatism 2005, 52:1700-1710.
98. Pickens S.R., Chamberlain N.D., Volin M.V., Pope R.M., Talarico N.E., Mandelin A.M., et al. Characterization of interleukin-7 and interleukin-7 receptor in the pathogenesis of rheumatoid arthritis. Arthritis and Rheumatism 2011, 63:2884-2893.
99. Hartgring S.A., Bijlsma J.W., Lafeber F.P., van Roon J.A. Interleukin-7 induced immunopathology in arthritis. Annals of the Rheumatic Diseases 2006, 65(Suppl.3):iii69-iii74.
100. van Roon J.A., Hartgring S.A., Wenting-van Wijk M., Jacobs K.M., Tak P.P., Bijlsma J.W., et al. Persistence of interleukin 7 activity and levels on tumour necrosis factor alpha blockade in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2007, 66:664-669.
101. Hartgring S.A., van Roon J.A., Wenting-van Wijk M., Jacobs K.M., Jahangier Z.N., Willis C.R., et al. Elevated expression of interleukin-7 receptor in inflamed joints mediates interleukin-7-induced immune activation in rheumatoid arthritis. Arthritis and Rheumatism 2009, 60:2595-2605.
102. Chen Z., Kim S.J., Chamberlain N.D., Pickens S.R., Volin M.V., Volkov S., et al. The novel role of IL-7 Ligation to IL-7 receptor in myeloid cells of rheumatoid arthritis and collagen-induced arthritis. Journal of Immunology 2013, 190:5256-5266.
103. Deshpande P., Cavanagh M.M., Le Saux S., Singh K., Weyand C.M., Goronzy J.J. IL-7- and IL-15-mediated TCR sensitization enables T cell responses to self-antigens. Journal of Immunology 2013, 190:1416-1423.
104. Singh K., Deshpande P., Pryshchep S., Colmegna I., Liarski V., Weyand C.M., et al. ERK-dependent T cell receptor threshold calibration in rheumatoid arthritis. Journal of Immunology 2009, 183:8258-8267.
105. Badot V., Durez P., Van den Eynde B.J., Nzeusseu-Toukap A., Houssiau F.A., Lauwerys B.R. Rheumatoid arthritis synovial fibroblasts produce a soluble form of the interleukin-7 receptor in response to pro-inflammatory cytokines. Journal of Cellular and Molecular Medicine 2011, 15:2335-2342.
106. Bikker A., van Woerkom J.M., Kruize A.A., Wenting-van Wijk M., de Jager W., Bijlsma J.W., et al. Increased expression of interleukin-7 in labial salivary glands of patients with primary Sjogren's syndrome correlates with increased inflammation. Arthritis and Rheumatism 2010, 62:969-977.
107. Bikker A., Kruize A.A., Wenting M., Versnel M.A., Bijlsma J.W., Lafeber F.P., et al. Increased interleukin (IL)-7Ralpha expression in salivary glands of patients with primary Sjogren's syndrome is restricted to T cells and correlates with IL-7 expression, lymphocyte numbers and activity. Annals of the Rheumatic Diseases 2012, 71:1027-1033.
108. Jin J.O., Kawai T., Cha S., Yu Q. Interleukin-7 enhances Th1 response to promote the development of Sjogren's syndrome-like autoimmune exocrinopathy. Arthritis and Rheumatism 2013, 10.1002/art.38007.
109. Kanai T., Watanabe M., Hibi T. Systemically circulating colitogenic memory CD4+T cells may be an ideal target for the treatment of inflammatory bowel diseases. The Keio Journal of Medicine 2009, 58:203-209.
110. Strober W., Fuss I.J., Blumberg R.S. The immunology of mucosal models of inflammation. Annual Review of Immunology 2002, 20:495-549.
111. Watanabe M., Ueno Y., Yajima T., Okamoto S., Hayashi T., Yamazaki M., et al. Interleukin 7 transgenic mice develop chronic colitis with decreased interleukin 7 protein accumulation in the colonic mucosa. The Journal of Experimental Medicine 1998, 187:389-402.
112. von Freeden-Jeffry U., Davidson N., Wiler R., Fort M., Burdach S., Murray R. IL-7 deficiency prevents development of a non-T cell non-B cell-mediated colitis. Journal of Immunology 1998, 161:5673-5680.
113. Shinohara T., Nemoto Y., Kanai T., Kameyama K., Okamoto R., Tsuchiya K., et al. Upregulated IL-7 receptor alpha expression on colitogenic memory CD4+ T cells may participate in the development and persistence of chronic colitis. Journal of Immunology 2011, 186:2623-2632.
114. Okada E., Yamazaki M., Tanabe M., Takeuchi T., Nanno M., Oshima S., et al. IL-7 exacerbates chronic colitis with expansion of memory IL-7Rhigh CD4+ mucosal T cells in mice. American Journal of Physiology Gastrointestinal and Liver Physiology 2005, 288:G745-G754.
115. Tomita T., Kanai T., Nemoto Y., Fujii T., Nozaki K., Okamoto R., et al. Colitogenic CD4+ effector-memory T cells actively recirculate in chronic colitic mice. Inflammatory Bowel Diseases 2008, 14:1630-1640.
116. Shalapour S., Deiser K., Kuhl A.A., Glauben R., Krug S.M., Fischer A., et al. Interleukin-7 links T lymphocyte and intestinal epithelial cell homeostasis. PloS One 2012, 7:e31939.
117. Watanabe M., Ueno Y., Yajima T., Iwao Y., Tsuchiya M., Ishikawa H., et al. Interleukin 7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes. The Journal of Clinical Investigation 1995, 95:2945-2953.
118. Nemoto Y., Kanai T., Takahara M., Oshima S., Nakamura T., Okamoto R., et al. Bone marrow-mesenchymal stem cells are a major source of interleukin-7 and sustain colitis by forming the niche for colitogenic CD4 memory T cells. Gut 2012, 10.1136/gutjnl-2012-302029.
119. Willis C.R., Seamons A., Maxwell J., Treuting P.M., Nelson L., Chen G., et al. Interleukin-7 receptor blockade suppresses adaptive and innate inflammatory responses in experimental colitis. Journal of Inflammation 2012, 9:39.
120. Gonzalez-Quintial R., Lawson B.R., Scatizzi J.C., Craft J., Kono D.H., Baccala R., et al. Systemic autoimmunity and lymphoproliferation are associated with excess IL-7 and inhibited by IL-7Ralpha blockade. PloS One 2011, 6:e27528.
121. Badot V., Luijten R.K., van Roon J.A., Depresseux G., Aydin S., Van den Eynde B.J., et al. Serum soluble interleukin 7 receptor is strongly associated with lupus nephritis in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases 2013, 72:453-456.
122. Bonifati C., Trento E., Cordiali-Fei P., Carducci M., Mussi A., D'Auria L., et al. Increased interleukin-7 concentrations in lesional skin and in the sera of patients with plaque-type psoriasis. Clinical Immunology and Immunopathology 1997, 83:41-44.
123. Szepietowski J.C., Bielicka E., Nockowski P., Noworolska A., Wasik F. Increased interleukin-7 levels in the sera of psoriatic patients: lack of correlations with interleukin-6 levels and disease intensity. Clinical and Experimental Dermatology 2000, 25:643-647.
124. Stabler T., Piette J.C., Chevalier X., Marini-Portugal A., Kraus V.B. Serum cytokine profiles in relapsing polychondritis suggest monocyte/macrophage activation. Arthritis and Rheumatism 2004, 50:3663-3667.
125. Yang Y., Xiao X., Li F., Du L., Kijlstra A., Yang P. Increased IL-7 expression in Vogt-Koyanagi-Harada disease. Investigative Ophthalmology & Visual Science 2012, 53:1012-1017.
126. Gershwin M.E., Shoenfeld Y. Chella David: a lifetime contribution in translational immunology. Journal of Autoimmunity 2011, 37:59-62.
127. Jamin C., Renaudineau Y., Pers J.O. Pierre Youinou: when intuition and determination meet autoimmunity. Journal of Autoimmunity 2012, 39:117-120.
128. Tzioufas A.G., Kapsogeorgou E.K., Moutsopoulos H.M. Pathogenesis of Sjogren's syndrome: what we know and what we should learn. Journal of Autoimmunity 2012, 39:4-8.
129. Abbas A.K., Burakoff S.J., Gefter M.L., Greene M.I. Tlymphocyte-mediated suppression of myeloma function invitro. III. Regulation of antibody production in hybrid myeloma cells by T lymphocytes. The Journal of Experimental Medicine 1980, 152:969-978.
130. Katzman S.D., Hoyer K.K., Dooms H., Gratz I.K., Rosenblum M.D., Paw J.S., et al. Opposing functions of IL-2 and IL-7 in the regulation of immune responses. Cytokine 2011, 56:116-121.